Loading stock data…
PCRX
$24.44-1.05 (-4.12%)
Market ClosedLast close May 1
Pacira BioSciences, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Pacira BioSciences, Inc. in the Healthcare sector is trading at $24.44. The stock is currently 12% below its 52-week high of $27.64, remaining 3.4% above its 200-day moving average. Technical signals show neutral RSI of 53 and bullish MACD crossover, explaining why PCRX maintains its current momentum and trend strength. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 53) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$24.44
Potential Downside
90.8%
Whystock Fair Value$2.25
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus7 analysts
Buy
Mean target$29.29+19.8%
Range$23.00 – $38.00
Fundamentals
Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupiva...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.07B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
155.50
Beta
Defensive asset. Lower volatility than the S&P 500.
0.20
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-18.39%
Volume
Today's trading volume
1.67M
Recent News
Assessing Pacira BioSciences (PCRX) Valuation After Earnings Update And New EXPAREL Real World Data
Pacira BioSciences (PCRX) has just combined a fresh set of quarterly numbers with new real world data on its lead non opioid pain drug, EXPAREL. Together, these developments give you several angles to assess the stock. See our latest analysis for Pacira BioSciences. The fresh EXPAREL study and first quarter update arrive as Pacira’s 30 day share price return of 7.67% and 90 day gain of 15.17% contrast with a 1 year total shareholder return decline of 7.60%. This signals improving short term...
Pacira Q1 Earnings Miss Estimates on Higher Costs, Revenues Rise Y/Y
PCRX Q1 earnings miss estimates as rising costs weigh on profit, but revenues top expectations on Exparel demand and growth from Zilretta and iovera.
Pacira BioSciences' CFO Sold 12,941 Shares for $326,000 Before Its Q1 Earnings Release
Pacira BioSciences, a leader in non-opioid pain management, reported a notable insider sale amid ongoing option exercise activity.
Pacira BioSciences Inc (PCRX) Q1 2026 Earnings Call Highlights: Strong Product Growth Amidst ...
Pacira BioSciences Inc (PCRX) reports robust sales growth for EXPAREL, ZILRETTA, and iovera, while navigating weather disruptions and rising expenses.
Pacira BioSciences Q1 Earnings Call Highlights
Pacira BioSciences (NASDAQ:PCRX) reported first-quarter 2026 results that management said reflect continued momentum under its “5x30” strategy, highlighted by year-over-year growth across its three commercial products and reiterated full-year guidance. Chief Executive Officer Frank D. Lee said the